Adult Orbital Tumors

Overview

Most orbital tumors in adults are benign and slow-growing. The most common primary orbital tumor is the cavernous venous malformation (the historical “cavernous hemangioma”); the most common orbital malignancy in adults is lymphoma. Age, growth rate, the presence or absence of pain, and the imaging pattern narrow the diagnosis before any biopsy — the entities below are ordered roughly from most to least common.

← Back to Orbital Tumors overview · Pediatric orbital tumors →

Cavernous Venous Malformation (Cavernous “Hemangioma”)

The most common primary orbital tumor in adults. Despite the historical name, it is a venous malformation — a well-encapsulated mass of enlarged vascular spaces within the muscle cone. It typically presents in women in the 4th–5th decade (ages 30–60) with slowly progressive painless axial proptosis. CT shows a well-defined, homogeneously enhancing intraconal mass. MRI demonstrates progressive centripetal enhancement. Treatment is surgical excision when vision is threatened or proptosis is cosmetically significant; asymptomatic lesions can be observed.

Full guide: Cavernous Hemangioma — symptoms, MRI findings, and when to operate →

Hemangiopericytoma (Solitary Fibrous Tumor)

Solitary fibrous tumor / hemangiopericytoma is a mesenchymal tumor of perivascular cells that can arise anywhere in the orbit. It is less well-encapsulated than cavernous hemangioma and may have locally invasive behavior. Complete surgical excision is the treatment of choice; incomplete excision leads to recurrence. A subset of cases behaves aggressively with distant metastasis. Pathologic grading (WHO) guides adjuvant treatment decisions.

Lacrimal Gland Tumors

The lacrimal gland, located in the superolateral orbit, gives rise to a spectrum of lesions. The clinical rule of “50/50” applies: approximately 50% of lacrimal gland masses are epithelial neoplasms and 50% are inflammatory or lymphoid. Of the epithelial tumors, 50% are benign mixed tumors (pleomorphic adenoma) and 50% are malignant.

• Pleomorphic adenoma — the most common lacrimal gland epithelial tumor; presents over months to years with painless superolateral orbital fullness and downward-inward displacement of the globe. CT shows a well-defined, rounded mass in the lacrimal gland fossa that scallops and expands the bone without destroying it — a benign remodeling pattern that helps distinguish it from the bone destruction of adenoid cystic carcinoma. Complete excision with intact pseudocapsule is mandatory — capsule rupture or piecemeal removal risks recurrence and malignant transformation to carcinoma ex pleomorphic adenoma
• Adenoid cystic carcinoma — the most common malignant lacrimal gland tumor; characterized by perineural invasion and pain. Presents more rapidly than pleomorphic adenoma, often with pain. Despite aggressive treatment (exenteration + radiation), recurrence rates are high and prognosis is poor. High index of suspicion is warranted for any painful, rapidly progressive lacrimal gland mass
• Dacryoadenitis — inflammatory swelling of the lacrimal gland from infection (acute: Staphylococcus, gonorrhea; chronic: sarcoidosis, IgG4-related disease, sjögren’s)

Orbital Lymphoma

Orbital lymphoma is the most common malignant orbital tumor in adults over 60, accounting for 10–15% of all orbital tumors. Most are B-cell non-Hodgkin lymphomas, predominantly extranodal marginal zone lymphoma (EMZL, also called MALT lymphoma). Orbital and conjunctival lymphoma may be the initial presentation of systemic disease or may arise as a primary ocular adnexal tumor.

Clinical features: Painless, slowly progressive proptosis, lid swelling, or salmon-colored conjunctival mass. The classic imaging finding is a mass that “molds” around orbital structures without bone erosion — reflecting the lymphoma’s soft consistency.

Management: Biopsy followed by systemic staging workup (CT chest/abdomen/pelvis, bone marrow biopsy). Low-grade localized orbital EMZL is treated with low-dose external beam radiation (24 Gy) with >90% local control. Systemic or high-grade disease requires chemotherapy (R-CHOP); anti-CD20 therapy (rituximab) is used for B-cell lymphomas.

Neurofibroma and Plexiform Neurofibroma

Orbital neurofibromas may be solitary or plexiform. Plexiform neurofibroma is pathognomonic of Neurofibromatosis type 1 (NF-1) and involves the periorbital and orbital tissues diffusely. It presents in childhood as a “bag of worms” soft tissue mass with S-shaped ptosis and the classic NF-1 “absent greater wing of sphenoid” on imaging (pulsating proptosis due to bony defect). Management is challenging — surgical debulking reduces volume but complete resection is impossible; MEK inhibitor therapy (selumetinib) is now FDA-approved for pediatric plexiform neurofibromas.

Orbital Schwannoma

Schwannomas arise from the Schwann cells of peripheral nerves and are well-encapsulated, slow-growing tumors. In the orbit, they typically arise from peripheral branches of the trigeminal nerve (CN V) and present as painless, slowly progressive proptosis over years. CT shows a well-defined, enhancing mass. Surgical excision with preservation of the nerve capsule is curative; the capsule plane allows safe dissection.

Sphenoid Wing Meningioma

Meningiomas arising from the sphenoid wing invade the orbit through the superior orbital fissure or directly through bone, producing progressive proptosis, visual loss, and motility restriction. The “en plaque” variant grows as a flat sheet along the bone rather than a discrete mass. CT characteristically shows hyperostosis (bony thickening) of the sphenoid wing — a distinctive feature not seen with orbital lymphoma or metastases.

Management is complex, often requiring multidisciplinary planning with neurosurgery. Surgical decompression is indicated for progressive visual loss; total resection is rarely achievable given the infiltrative growth. Stereotactic radiosurgery (Gamma Knife) provides tumor control for smaller lesions. Observation is appropriate for asymptomatic or slowly progressive disease in older patients.

Orbital Pseudotumor (Idiopathic Orbital Inflammatory Syndrome)

Orbital pseudotumor — formally termed idiopathic orbital inflammatory syndrome (IOIS) — is a benign, non-specific inflammatory condition of the orbit without identifiable local or systemic cause. It is the most common painful orbital mass in adults and must be distinguished from the tumors described above, as treatment is fundamentally different (anti-inflammatory rather than surgical).

Subtypes by Location

• Myositic: Extraocular muscle inflammation (orbital myositis) — pain with eye movement; muscle thickening including the tendon (distinguishes from thyroid eye disease, where tendons are spared)
• Dacryoadenitis: Lacrimal gland inflammation — superolateral lid swelling, S-shaped lid deformity, palpable mass
• Anterior: Anterior orbital fat and connective tissue
• Diffuse: Entire orbit involved — most severe; may cause compressive optic neuropathy
• Apical (Tolosa-Hunt Syndrome): Inflammation at the orbital apex / cavernous sinus causing painful ophthalmoplegia (CN III, IV, VI palsies)

Presentation

The classic triad: acute painful proptosis + inflammatory eyelid/conjunctival signs + dramatic response to corticosteroids within 24–48 hours. Pain is the key distinguishing feature — most other orbital masses are painless.

Diagnosis

MRI with gadolinium is the preferred imaging modality. Laboratory workup excludes systemic causes: CBC, CRP, thyroid function, ACE (sarcoidosis), ANCA (GPA/Wegener’s), ANA, and serum IgG4 (IgG4-related orbital disease). Orbital biopsy is required when the diagnosis is uncertain or when the lesion fails to respond to steroids.

IgG4-Related Orbital Disease

IgG4-ROD is now recognized as a distinct clinicopathological entity separate from idiopathic IOIS. It is characterized by elevated serum IgG4, dense IgG4+ plasma cell infiltration on biopsy, storiform fibrosis, and a tendency to involve multiple organs (pancreas, salivary glands, kidneys). It responds to steroids initially but frequently recurs; rituximab has shown promise for refractory cases.

Treatment

High-dose oral prednisone (1 mg/kg/day) is first-line. Response within 24–48 hours is characteristic and diagnostically informative — failure to respond should prompt biopsy. Recurrent or steroid-dependent disease is treated with low-dose orbital radiation (20 Gy) or steroid-sparing immunosuppression (methotrexate, mycophenolate, rituximab).